144 related articles for article (PubMed ID: 38250137)
21. Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status.
Fujieda S; Matsune S; Takeno S; Ohta N; Asako M; Bachert C; Inoue T; Takahashi Y; Fujita H; Deniz Y; Rowe P; Ortiz B; Li Y; Mannent LP
Allergy; 2022 Jan; 77(1):186-196. PubMed ID: 33993501
[TBL] [Abstract][Full Text] [Related]
22. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps.
Pelaia C; Benfante A; Busceti MT; Caiaffa MF; Campisi R; Carpagnano GE; Crimi N; D'Amato M; Foschino Barbaro MP; Maglio A; Minenna E; Nolasco S; Paglino G; Papia F; Pelaia G; Portacci A; Ricciardi L; Scichilone N; Scioscia G; Triggiani M; Valenti G; Vatrella A; Crimi C
Front Immunol; 2023; 14():1121237. PubMed ID: 37063895
[TBL] [Abstract][Full Text] [Related]
23. Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function.
Pavord ID; Siddiqui S; Papi A; Corren J; Sher LD; Bardin P; Langton D; Park HS; Rice MS; Deniz Y; Rowe P; Staudinger HW; Patel N; Ruddy M; Graham NMH; Teper A
J Asthma Allergy; 2020; 13():701-711. PubMed ID: 33364789
[TBL] [Abstract][Full Text] [Related]
24. Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma.
Corren J; Katelaris CH; Castro M; Maspero JF; Ford LB; Halpin DMG; Rice MS; Radwan A; Deniz Y; Rowe PJ; Teper A; Djandji M
Eur Respir J; 2021 Oct; 58(4):. PubMed ID: 34266940
[TBL] [Abstract][Full Text] [Related]
25. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.
Bachert C; Zinreich SJ; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Amin N; Joish VN; Fan C; Zhang D; Staudinger H; Pirozzi G; Graham NMH; Khan A; Mannent LP
Rhinology; 2020 Feb; 58(1):10-17. PubMed ID: 31671432
[TBL] [Abstract][Full Text] [Related]
26. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis.
Heffler E; Saccheri F; Bartezaghi M; Canonica GW
Clin Transl Allergy; 2020; 10():25. PubMed ID: 32607141
[TBL] [Abstract][Full Text] [Related]
28. Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps.
Hoy SM
Drugs; 2020 May; 80(7):711-717. PubMed ID: 32240527
[TBL] [Abstract][Full Text] [Related]
29. Improvement in Health-Related Quality of Life with Dupilumab in Patients with Moderate-to-Severe Asthma with Comorbid Chronic Rhinosinusitis with/without Nasal Polyps: An Analysis of the QUEST Study.
Hopkins C; Buchheit KM; Heffler E; Cohen NA; Olze H; Khan AH; Msihid J; Siddiqui S; Nash S; Jacob-Nara JA; Rowe PJ; Deniz Y
J Asthma Allergy; 2022; 15():767-773. PubMed ID: 35698581
[TBL] [Abstract][Full Text] [Related]
30. Impact of Exacerbation History on Dupilumab Efficacy in Children with Uncontrolled Moderate-to-Severe Asthma: LIBERTY ASTHMA VOYAGE Study.
Guilbert TW; Tolcachier A; Fiocchi AG; Katelaris CH; Phipatanakul W; Begin P; de Mir I; Altincatal A; Gall R; Ledanois O; Radwan A; Jacob-Nara JA; Deniz Y; Rowe PJ
J Asthma Allergy; 2024; 17():143-159. PubMed ID: 38476213
[TBL] [Abstract][Full Text] [Related]
31. Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma.
Corren J; Katelaris CH; Castro M; Maspero JF; Humbert M; Halpin DMG; Altincatal A; Pandit-Abid N; Soler X; Radwan A; Jacob-Nara JA; Deniz Y; Rowe PJ
ERJ Open Res; 2023 Sep; 9(5):. PubMed ID: 37859672
[TBL] [Abstract][Full Text] [Related]
32. Conjunctivitis in dupilumab clinical trials.
Akinlade B; Guttman-Yassky E; de Bruin-Weller M; Simpson EL; Blauvelt A; Cork MJ; Prens E; Asbell P; Akpek E; Corren J; Bachert C; Hirano I; Weyne J; Korotzer A; Chen Z; Hultsch T; Zhu X; Davis JD; Mannent L; Hamilton JD; Teper A; Staudinger H; Rizova E; Pirozzi G; Graham NMH; Shumel B; Ardeleanu M; Wollenberg A
Br J Dermatol; 2019 Sep; 181(3):459-473. PubMed ID: 30851191
[TBL] [Abstract][Full Text] [Related]
33. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps.
Peters AT; Han JK; Hellings P; Heffler E; Gevaert P; Bachert C; Xu Y; Chuang CC; Neupane B; Msihid J; Mannent LP; Guyot P; Kamat S
J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2461-2471.e5. PubMed ID: 33548517
[TBL] [Abstract][Full Text] [Related]
34. Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma.
Papi A; Corren J; Castro M; Domingo C; Rogers L; Chapman KR; Jackson DJ; Daizadeh N; Pandit-Abid N; Gall R; Jacob-Nara JA; Rowe PJ; Deniz Y; Ortiz B
Allergy; 2023 Jan; 78(1):233-243. PubMed ID: 35899469
[TBL] [Abstract][Full Text] [Related]
35. Effect of Dupilumab in Korean Patients With Uncontrolled Moderate-to-Severe Asthma: A LIBERTY ASTHMA QUEST Sub-analysis.
Rhee CK; Park JW; Park HW; Cho YS
Allergy Asthma Immunol Res; 2022 Mar; 14(2):182-195. PubMed ID: 35255536
[TBL] [Abstract][Full Text] [Related]
36. The relationship of sinus opacification, olfaction and dupilumab efficacy in patients with CRSwNP.
Lee SE; Amin N; Mannent LP; Bachert C; Gross G; Cho SH; Praestgaard A; Siddiqui S; Nash S; Kamat S; Khan AH; Jacob Nara JA
Rhinology; 2023 Dec; 61(6):531-540. PubMed ID: 37453138
[TBL] [Abstract][Full Text] [Related]
37. Impact of Lung Function on Asthma Exacerbation Rates in Children Treated with Dupilumab: The VOYAGE Study.
Guilbert TW; Murphy KR; Hamelmann E; Ross KR; Gupta A; Fiocchi A; Xia C; Gall R; Ledanois O; Radwan A; Jacob-Nara JA; Rowe PJ; Deniz Y
J Asthma Allergy; 2024; 17():81-87. PubMed ID: 38347908
[TBL] [Abstract][Full Text] [Related]
38. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
Castro M; Corren J; Pavord ID; Maspero J; Wenzel S; Rabe KF; Busse WW; Ford L; Sher L; FitzGerald JM; Katelaris C; Tohda Y; Zhang B; Staudinger H; Pirozzi G; Amin N; Ruddy M; Akinlade B; Khan A; Chao J; Martincova R; Graham NMH; Hamilton JD; Swanson BN; Stahl N; Yancopoulos GD; Teper A
N Engl J Med; 2018 Jun; 378(26):2486-2496. PubMed ID: 29782217
[TBL] [Abstract][Full Text] [Related]
39. Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life Perspective.
Caminati M; Maule M; Benoni R; Bagnasco D; Beghè B; Braido F; Brussino L; Cameli P; Candeliere MG; Carpagnano GE; Costanzo G; Crimi C; D'Amato M; Del Giacco S; Guarnieri G; Yacoub MR; Micheletto C; Nicola S; Olivieri B; Pini L; Schiappoli M; Vaia R; Vianello A; Visca D; Spanevello A; Senna G
Biomedicines; 2024 Feb; 12(2):. PubMed ID: 38397992
[TBL] [Abstract][Full Text] [Related]
40. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis.
Boguniewicz M; Beck LA; Sher L; Guttman-Yassky E; Thaçi D; Blauvelt A; Worm M; Corren J; Soong W; Lio P; Rossi AB; Lu Y; Chao J; Eckert L; Gadkari A; Hultsch T; Ruddy M; Mannent LP; Graham NMH; Pirozzi G; Chen Z; Ardeleanu M
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1212-1223.e6. PubMed ID: 33453450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
